Profile
Prior to joining Radius Ventures on March 2007, Dr. McGibney was appointed head of European Clinical Development for Pfizer Central Research in 1992 and named Vice President of Clinical Research and a member of the Board of Directors of Pfizer Ltd in 1995.
Prior to leaving Pfizer in 2001, he was Senior Vice President of Pfizer Global Research and Development and Director of the R & D Laboratories in Sandwich, Kent, UK.
Dr. McGibney currently serves as chairman of the Development Advisory Board of Athersys, Inc., a Radius portfolio company.
Former positions of David McGibney
| Companies | Position | End |
|---|---|---|
Nxera Pharma UK Ltd.
Nxera Pharma UK Ltd. Pharmaceuticals: MajorHealth Technology Designs and develops new medicines targeting G protein-coupled receptors | Chief Tech/Sci/R&D Officer | 08/01/2014 |
Avidex Ltd.
Avidex Ltd. Pharmaceuticals: MajorHealth Technology Develops and discovers drugs for the treatment of cancer and autoimmune diseases | Director/Board Member | 03/12/2008 |
Fovea Pharmaceuticals SA
Fovea Pharmaceuticals SA Pharmaceuticals: MajorHealth Technology Develops and commercializes drugs for the treatment of ocular diseases | Director/Board Member | - |
| PFIZER INC. | Corporate Officer/Principal | - |
Training of David McGibney
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Private companies | 5 |
|---|---|
Pfizer Inc.
Pfizer Inc. Pharmaceuticals: MajorHealth Technology Engages in discovery, development, manufacturing, marketing, sale and distribution of biopharmaceutical products & ingredients | Health Technology |
University of Leeds
University of Leeds Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Avidex Ltd.
Avidex Ltd. Pharmaceuticals: MajorHealth Technology Develops and discovers drugs for the treatment of cancer and autoimmune diseases | Health Technology |
Fovea Pharmaceuticals SA
Fovea Pharmaceuticals SA Pharmaceuticals: MajorHealth Technology Develops and commercializes drugs for the treatment of ocular diseases | Health Technology |
Nxera Pharma UK Ltd.
Nxera Pharma UK Ltd. Pharmaceuticals: MajorHealth Technology Designs and develops new medicines targeting G protein-coupled receptors | Health Technology |
- Stock Market
- Insiders
- David McGibney
















